Atezolizumab

Generic Name: Atezolizumab

Brand Names: Tecentriq

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1380723-44-3

Unique Ingredient Identifier: 52CMI0WC3Y

Background: Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.

Indication: Atezolizumab has approved indications for the following conditions:

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Hepatocellular Carcinoma (HCC)

Melanoma

Alveolar Soft Part Sarcoma (ASPS)

Associated Conditions: Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma

Associated Therapies: -

Clinical Trials

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Phase 1

Terminated

Conditions: Metastatic Solid Neoplasm
Lymphoma

Interventions: Drug: SYNB1891
Drug: Atezolizumab

First Posted Date: 2019-11-18

Last Posted Date: 2024-05-03

Lead Sponsor: Synlogic

Target Recruit Count: 32

Registration Number: NCT04167137

Locations: 🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States
🇺🇸
Ohio State University College of Medicine, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 3 locations

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Phase 1

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Atezolizumab
Biological: RO7198457
Drug: mFOLFIRINOX

First Posted Date: 2019-11-13

Last Posted Date: 2024-12-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 29

Registration Number: NCT04161755

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities), Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison, New York, United States

and more 4 locations

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active, not recruiting

Conditions: Breast Cancer

Interventions: Drug: Ado-trastuzumab emtamsine
Drug: Atezolizumab
Drug: Capecitabine
Drug: Bevacizumab
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-11-08

Last Posted Date: 2024-11-05

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 2907

Registration Number: NCT04158258

Locations: 🇦🇷
Instituto Alexander Fleming, Buenos Aires, Argentina
🇦🇷
Instituto de Oncología de Rosario, Rosario, Argentina
🇦🇷
Sanatorio de la Mujer, Rosario, Argentina

and more 27 locations

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Phase 3

Active, not recruiting

Conditions: Triple-Negative Breast Cancer

Interventions: Drug: Atezolizumab
Drug: Nab-Paclitaxel

First Posted Date: 2019-11-04

Last Posted Date: 2024-10-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 184

Registration Number: NCT04148911

Locations: 🇫🇷
Hopital Avicenne; Cancerologie, Bobigny, France
🇫🇷
Institut de Cancérologie de Bourgogne; Oncologie Médicale, Dijon, France
🇫🇷
Hôpital Franco-Britannique- Fondation Cognacq-Jay; Cancerologie, Levallois-Perret, France

and more 73 locations

Treatment Of Metastatic Bladder Cancer at the Time Of Biochemical reLApse Following Radical Cystectomy

Phase 2

Recruiting

Conditions: Bladder Cancer
Bladder Cancer, Metastatic

Interventions: Drug: Atezolizumab

First Posted Date: 2019-10-24

Last Posted Date: 2022-08-08

Lead Sponsor: Jørgen Bjerggaard Jensen

Target Recruit Count: 282

Registration Number: NCT04138628

Locations: 🇩🇰
Aarhus University Hospital, Aarhus, Denmark
🇩🇰
Herlev Hospital, Herlev, Denmark
🇩🇰
Aalborg Universitetshospital, Aalborg, Denmark

and more 2 locations

Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

Phase 1

Active, not recruiting

Conditions: Invasive Bladder Cancer

Interventions: Drug: Atezolizumab
Drug: BCG

First Posted Date: 2019-10-21

Last Posted Date: 2024-05-21

Lead Sponsor: Fundacion Oncosur

Target Recruit Count: 40

Registration Number: NCT04134000

Locations: 🇪🇸
Hospital 12 de Octubre, Madrid, Spain

A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Genetic: delolimogene mupadenorepvec
Biological: atezolizumab

First Posted Date: 2019-10-11

Last Posted Date: 2023-08-29

Lead Sponsor: Lokon Pharma AB

Target Recruit Count: 26

Registration Number: NCT04123470

Locations: 🇺🇸
Cedars-Sinai Medical Center, The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸
Baylor St Luke's Medical Center, Houston, Texas, United States
🇸🇪
Uppsala University Hospital, Uppsala, Sweden

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma

Interventions: Drug: IN10018
Drug: Cobimetinib
Biological: Atezolizumab

First Posted Date: 2019-09-30

Last Posted Date: 2024-11-28

Lead Sponsor: InxMed (Shanghai) Co., Ltd.

Target Recruit Count: 120

Registration Number: NCT04109456

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center., Miami, Florida, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

Microbiome Immunotherapy Toxicity and Response Evaluation

Recruiting

Conditions: Melanoma
Renal Cancer
Lung Cancer

Interventions: Drug: Nivolumab
Drug: Durvalumab
Drug: Pembrolizumab
Drug: Ipilimumab
Drug: Tremelimumab
Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-27

Last Posted Date: 2023-02-16

Lead Sponsor: CCTU- Cancer Theme

Target Recruit Count: 1800

Registration Number: NCT04107168

Locations: 🇬🇧
University Hospitals Dorest NHS Foundation Trust, Bournemouth, United Kingdom
🇬🇧
Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

and more 10 locations

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Phase 3

Active, not recruiting

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2019-09-25

Last Posted Date: 2024-06-07

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 668

Registration Number: NCT04102098

Locations: 🇨🇳
Fujian Cancer Hospital, Fuzhou, China
🇨🇳
Guangxi Cancer Hospital of Guangxi Medical University, Nanning City, China
🇨🇳
The First Affiliate Hospital of Guangxi Medical University, Nanning, China

and more 135 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy